Insider · CIK 0001970438
Kristin Stafford
Files at NVCR (NovoCure Ltd), ZYME (Zymeworks Inc.). First filing Jun 4, 2025, latest Jun 3, 2026.
Kristin Stafford files SEC Form 4 as director and CFO at NVCR (NovoCure Ltd), and also at ZYME (Zymeworks Inc.). Since Jun 4, 2025, Kristin Stafford has reported 0 open-market buys worth $0 and 2 open-market sells worth $64k, the latest filed on Jun 3, 2026.
A track record needs three past buys with six months of prices behind them; Kristin Stafford has 0, so none is measured yet.
The newest scored trade: sold $46k of NVCR on Jun 2, 2026, filed Jun 3, 2026, scored 41 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $46k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | NovoCure Ltd | $46k 2,945 shares | -21% | +58% from low-14% from high | |
| 35Weak | NovoCure Ltd | $17k 999 shares | -25% | +17% from low-49% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +11,610 | $0.00 | $0 | 22,934 | Jun 5, 2026 |
| Jun 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +16,999 | $0.00 | $0 | 16,999 | Jun 5, 2026 |
| Jun 2, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -2,945 | $15.77 | $46k | 11,324 | Jun 3, 2026 |
| Apr 6, 2026 | ZYME Zymeworks Inc. | AGrant or award Stock Option (Right to Buy)derivative | +178,000 | $0.00 | $0 | 178,000 | Apr 7, 2026 |
| Apr 6, 2026 | ZYME Zymeworks Inc. | AGrant or award Restricted Stock Unitderivative | +119,000 | $0.00 | $0 | 119,000 | Apr 7, 2026 |
| Apr 6, 2026 | ZYME Zymeworks Inc. | AGrant or award Restricted Stock Unitderivative | +50,000 | $0.00 | $0 | 50,000 | Apr 7, 2026 |
| Jun 4, 2025 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +11,215 | $0.00 | $0 | 14,269 | Jun 6, 2025 |
| Jun 4, 2025 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +16,697 | $0.00 | $0 | 16,697 | Jun 6, 2025 |
| Jun 3, 2025 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -999 | $17.28 | $17k | 3,054 | Jun 4, 2025 |
Questions about Kristin Stafford
Answered from the filings on this page, as of the latest one.
Is Kristin Stafford buying or selling?
In the last 12 months Kristin Stafford reported 0 open-market buys worth $0 and 1 open-market sell worth $46k on SEC Form 4; the latest was sold $46k of NVCR on Jun 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Kristin Stafford's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kristin Stafford has 0.
Where does Kristin Stafford file Form 4?
Kristin Stafford has filed Form 4 at NVCR (NovoCure Ltd); ZYME (Zymeworks Inc.) as EVP, Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.